Colorectal Cancer (CRC) Terminated Phase 2 Trials for Regorafenib (DB08896)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

IndicationStatusPhase
DBCOND0031867 (Colorectal Cancer (CRC))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06006923
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal CancerTreatment
NCT02581059
Efficacy of Ginseng for Patients on RegorafenibTreatment
NCT03099486
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRCTreatment
NCT02119676
Study of Ruxolitinib in Colorectal Cancer PatientsTreatment